Then, in order to prove that the promotion effect of USP5 on the development of liver cancer was a common phenomenon in HCC and the potential value of targeting USP5 in the treatment of HCC, we used the xenograft nude mice model composed of another live cell line HepG2 cells to further reveal that the treatment of degrasyn targeting USP5 resulted in a decrease of the HCC tumor growth (Figure 6H, Figure S5D). The gene discussed is USP5; the disease is liver cancer.